Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
A review of electronic medical records found similar associations between opioid-using patients who reported and did not report fentanyl use.
Read Full NewsPsychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.
Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.
In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.
A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.
In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.
A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.
In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.
1.
T-DXd Reduces Residual Disease in Early Breast Cancer
2.
'Dawson's Creek' Star Has Cancer; Radiotherapy Tattoos; Case of 'Petticoat' Cancer
3.
Additional Proof of the Different Cognitive Effects of ARSIs for Prostate Cancer.
4.
After HSCT, a longer course of letermovir prophylaxis decreased the risk of cytomegalovirus infection.
5.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
1.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
2.
Cardiotoxicity Beyond Anthracyclines: Redefining Risk in the Cardio-Oncology Era
3.
Breaking Barriers in Cancer Treatment: The Role of Innovative Oncology Drugs
4.
Beyond the Tumor: Emerging Frontiers in Cancer Systems Biology
5.
Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
2.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
5.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge